Hanmi seeks to gain on Wegovy with its own weight-loss drug
Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press conference held in San Francisco, California, on Jan. 15. [LEE JAE-LIM] SAN FRANCISCO — Hanmi Pharmaceutical aims to disrupt the obesity drug market currently led by Eli Lilly and Novo Nordisk with its own diverse range of weight-loss treatments tailored to meet the unique needs of patients,
'Probably going to be the most prescribed drug'; The future of weight loss drugs
Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.
How easy is it to get weight loss drugs?
It's not just celebrities and TikTok creators jumping on the weight loss drug hype - more than 500,000 people in the UK are now taking either Mounjaro or Wegovy, with experts predicting a nationwide fall in obesity rates.
How weight-loss drugs will impact restaurants
The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
New weight loss pill to be approved by early 2026: Eli Lilly
The weight loss pill aims to compete with popular injectable treatments like Eli Lilly's own Zepbound and Novo Nordisk's Wegovy, which currently dominate the space. If approved, orforglipron would offer a pill alternative to the current injectables,
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Zealand Seeks to Usurp Wegovy, Zepbound With New Obesity Drug
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
Scientist issues weight loss jab warning and says 'should be taken for life'
Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
valuepenguin2d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price or $325 per month after insurance. Find Cheap Health Insurance Quotes in Your Area Weight ...
The Next Web5d
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.